These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Conversion enzyme inhibitors in the treatment of chronic congestive cardiac failure. Physiopathologic bases of their use]. Garabedian VG Presse Med; 1985 Dec; 14(44):2264-7. PubMed ID: 3003732 [TBL] [Abstract][Full Text] [Related]
43. Cardiac failure XIV. Treatment by modification of circulatory dynamics. Cohn JN Hosp Pract (Off Ed); 1984 Aug; 19(8):37-52. PubMed ID: 6430933 [No Abstract] [Full Text] [Related]
44. [The role of peripherally acting drugs in the treatment of chronic heart failure]. Dietz R Verh Dtsch Ges Inn Med; 1991; 97():184-7. PubMed ID: 1808883 [No Abstract] [Full Text] [Related]
45. [Value of training-induced effects on arterial vascular system and skeletal muscles in therapy of NYHA II/III heart failure]. Huonker M; Keul J Z Kardiol; 2001 Nov; 90(11):813-23. PubMed ID: 11771449 [TBL] [Abstract][Full Text] [Related]
46. Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. Packer M J Am Coll Cardiol; 1988 Nov; 12(5):1299-317. PubMed ID: 2844873 [TBL] [Abstract][Full Text] [Related]
47. Regional blood flow supply and demand in heart failure. Levine TB; Levine AB Am Heart J; 1990 Dec; 120(6 Pt 2):1547-51. PubMed ID: 2248211 [TBL] [Abstract][Full Text] [Related]
48. Peripheral adaptations in congestive heart failure: a review. Just H Am J Med; 1991 May; 90(5B):23S-26S. PubMed ID: 2048569 [TBL] [Abstract][Full Text] [Related]
49. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Drexler H; Kurz S; Jeserich M; Münzel T; Hornig B Am J Cardiol; 1995 Nov; 76(15):13E-18E. PubMed ID: 7484881 [TBL] [Abstract][Full Text] [Related]
51. The push, the pull and the periphery. Oakley CM Aust N Z J Med; 1992 Oct; 22(5 Suppl):587-91. PubMed ID: 1449445 [TBL] [Abstract][Full Text] [Related]
52. [Regional blood flow in congestive cardiac failure and inhibition of angiotensin converting enzyme]. Garnier LF; François G; Raynaud PH; Brochier M Rev Med Interne; 1986 Nov; 7(5):548-53. PubMed ID: 3027822 [TBL] [Abstract][Full Text] [Related]
53. Reassessing the use of vasodilators in heart failure. Cole RT; Gheorghiade M; Georgiopoulou VV; Gupta D; Marti CN; Kalogeropoulos AP; Butler J Expert Rev Cardiovasc Ther; 2012 Sep; 10(9):1141-51. PubMed ID: 23098150 [TBL] [Abstract][Full Text] [Related]
54. Myths and truths of growth hormone and testosterone therapy in heart failure. Nguyen CT; Aaronson A; Morrissey RP; Agarwal M; Willix RD; Schwarz ER Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):711-20. PubMed ID: 21714602 [TBL] [Abstract][Full Text] [Related]
55. Peripheral factors in the management of congestive heart failure. Demopoulos L; LeJemtel TH Cardiovasc Drugs Ther; 1994 Feb; 8(1):75-82. PubMed ID: 8086331 [TBL] [Abstract][Full Text] [Related]
56. Resistance training improves vasoreactivity in end-stage heart failure patients on inotropic support. Dean AS; Libonati JR; Madonna D; Ratcliffe SJ; Margulies KB J Cardiovasc Nurs; 2011; 26(3):218-23. PubMed ID: 21263349 [TBL] [Abstract][Full Text] [Related]